Search results

Back
1 - 10 of 254 Search results
28 October 2020  - 2 mins read

28 October 2020  - 2 mins read

Liver Cancer Awareness Month – Rethink liver cancer

October is Liver Cancer Awareness Month and this year we are proud to be supporting the European Liver Patients Association (ELPA) with their campaign encouraging everyone to rethink liver cancer by bringing it to the forefront of conversations....

 -  22 February 2021

 -  22 February 2021

Ipsen announces new data from the Phase II CLARINET FORTE study which demonstrated preservation of quality of life when increasing dose frequencies of Somatuline® Autogel® (lanreotide)

PARIS, France, 22 February 2021  – Ipsen (Euronext: IPN; ADR: IPSEY) announced today a total of 9 abstracts presenting new data with a focus in NETs.1-10 These include data from the Phase II CLARINET FORTE study and data on the use of independent admi...

 -  18 September 2020

 -  18 September 2020

ESMO 2020: Phase II CLARINET FORTE results show increasing dose frequencies of Somatuline® Autogel® (lanreotide) allows patients with NETs to delay treatment escalation by up to 8.3 months 

Attachment...

 -  05 February 2021

 -  05 February 2021

Ipsen to showcase commitment to going beyond traditional outcome measures for patients living with renal cell carcinoma at ASCO GU 2021

...

 -  14 September 2020

 -  14 September 2020

Ipsen showcases commitment to patient-centric advances in oncology with record number of abstracts to be presented at ESMO 2020 Virtual Congress

...

 -  15 January 2021

 -  15 January 2021

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications

...

 -  10 September 2020

 -  10 September 2020

Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results

Attachment...

 -  30 November 2020

 -  30 November 2020

Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC)

Attachment...

 -  30 July 2020

 -  30 July 2020

Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am enco...

 -  08 October 2020

 -  08 October 2020

 Ipsen to present 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress taking place jointly with the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)

Attachment...

1 … 21 22 23 24 25 26